Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer
Author:
Affiliation:
1. Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
2. Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Oncology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14737140.2018.1432356
Reference86 articles.
1. Gene aberrations for precision medicine against lung adenocarcinoma
2. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
3. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Application of nanoformulations as a strategy to optimize chemotherapeutic treatment of glioblastoma: a systematic review;Journal of Toxicology and Environmental Health, Part B;2024-03-13
2. Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer;Beilstein Journal of Nanotechnology;2023-02-22
3. Identification of multi-target anti-cancer agents from TCM formula by in silico prediction and in vitro validation;Chinese Journal of Natural Medicines;2022-05
4. Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?;Critical Reviews in Oncology/Hematology;2021-10
5. Aidi injection, a traditional Chinese medicine extract, reverses Gefitinib resistance in non-small cell lung cancer cells;European Journal of Integrative Medicine;2021-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3